#Conference #Pentixapharm is attending #GermanFallConference by EF Equity Forum in Frankfurt, today. Join Andreas Eckert, our Co-Founder and Chairman of the Supervisory Board, during the presentation at 5 pm. We are looking forward to many exciting conversations. #HK #Herbstkonferenz #PLACEtoBE #HK24
Pentixapharm AG
Arzneimittelherstellung
improves the life of patients with malignant diseases through targeted molecular diagnostic and therapy
Info
improves the life of patients with malignant diseases through targeted molecular diagnostic and therapy
- Website
-
http://www.pentixapharm.com
Externer Link zu Pentixapharm AG
- Branche
- Arzneimittelherstellung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Würzburg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2019
Orte
-
Primär
Bismarckstr. 13
Würzburg, 97080, DE
-
Robert-Rössle Straße
Berlin, 13125, DE
Beschäftigte von Pentixapharm AG
-
Alexandra Eichten
Director Preclinical Pharmacology at Pentixapharm
-
Hakim Bouterfa
Managing Director PentixaPharm and Executive Board Member Eckert & Ziegler AG
-
Sezgin Kına
CMC Project Manager at PentixaPharm AG
-
Dirk Pleimes
Chief Medical Officer Pentixapharm AG, CEO/CMO Myelo Therapeutics GmbH Serial Founder & Biotechnology entrepreneur
Updates
-
Listen into the latest Beyond Biotech podcast episode of Labiotech.eu, in which Andreas Eckert, our Co-Founder and Chairman of the Supervisory Board, speaks about Pentixapharm AG's novel radiopharmaceutical pipeline, e.g. its exciting development plans of #PentixaFor in #PrimaryAldosteronism as common cause of hypertension, and the acquisition of the target discovery business of Glycotope GmbH. You can hear the full episode here: https://lnkd.in/dmyRFUpS #Radiopharma #BiotechInnovation #Podcast
-
-
For #Investors and #Media We have announced that the European Medicines Agency and the European Commission have granted an Orphan Drug Designation for #PentixaFor for the diagnosis and staging of Marginal Zone Lymphoma (MZL). PentixaFor is a novel diagnostic tracer for PET imaging targeting the C-X-C receptor 4, which is overexpressed on MZL cells. Preclinical and clinical studies indicate that PentixaFor has a high sensitivity and specificity for the diagnosis and staging of MZL, with potentially better outcomes than the currently used [18F]FDG. Pentixapharm currently sponsors a European Phase III clinical trial to assess the performance of PentixaFor for the imaging and staging in patients with confirmed MZL. You can read the full release here: https://lnkd.in/eRWxriSH #Pentixapharm #MarginalZoneLymphoma #CXCR4
-
-
Pentixapharm AG is featured in Fierce Pharma! 📰 You can read all about it in James Waldron’s article "Radiopharma-focused Pentixapharm picks up Glycotope's discovery unit for preclinical cancer antibodies" – Don’t miss out! 👉 https://lnkd.in/enJ9NQJS #Pentixapharm #Glycotope #Radiopharmaceuticals #Theranostics #HealthCareInnovation
-
For #Investors and #Media Today Pentixapharm AG has announced the acquisition of the target discovery business of Berlin-based Glycotope GmbH. This marks a significant milestone in our journey to develop novel targeted radiopharmaceuticals for various malignancies. 🔬 This acquisition encompasses a portfolio of preclinical antibodies against multiple oncology that can be developed into #radiopharmaceuticals. It also includes laboratories and equipment, cell banks, a tumor target database, along with a range of patents, licenses and other tangible assets. With this transaction we welcome 40 seasoned executives, R&D specialists, and administrators to our growing Pentixapharm team. This will significantly enhance our ability to develop effective diagnostics and therapeutics for patients. You can read the full release here: https://lnkd.in/eCXh35Nw #Pentixapharm #Glycotope #Acquisition #HealthcareInnovation #NuclearMedicine #Theranostics #Innovation #CXCR4 #ClinicalDevelopment
-
-
We are excited to welcome Prof. Dr. med. Marcus Quinkler, renowned specialist in #endocrinology, to our Supervisory Board. He is a recognized expert in primary aldosteronism (PA), the focus area of our Phase III lead program PENTIXAFOR (PTF-302) and will help to advance the ongoing clinical assessments of our novel #CXCR4-based radiopharmaceutical therapeutic and diagnostic programs. 🔍Read more: https://lnkd.in/eikvxn5D #HealthcareInnovation #RadioPharmaceuticals #NuclearMedicine #Theranostics #Innovation
-
-
Pentixapharm AG hat dies direkt geteilt
Die deutsche #Radiopharmazie bekommt einen neuen Player, und der stürmt gleich in die Phase 3 mit einem strahlenden Diagnostikum: Pentixapharm AG . Die Abspaltung von Eckert & Ziegler SE schafft mehr Bewegungsfreiheit und uns allen wohl einen IPO für die Branche im Herbst. Könnte spannend werden : transkript https://lnkd.in/dk2zntMk
Pentixapharm AG: Abspaltung von Eckert&Ziegler
transkript.de
-
For #Investors and #Media Today we are pleased to announce that Pentixapharm AG has received encouraging feedback from the FDA to directly proceed into a pivotal Phase III registration study with our radiopharmaceutical diagnostic, Ga68-PentixaFor, in Primary Aldosteronism (PA). This significant milestone paves the way for developing a first-in-class, non-invasive, and accurate alternative to adrenal venous sampling, potentially transforming diagnostic subtyping in PA and improving patient outcomes. PA is the most frequent cause of secondary hypertension (high blood pressure). 🌟 The minutes from the FDA also confirm that Ga68-PentixaFor addresses an unmet medical need for a serious condition and therefore meets two essential criteria for fast track and breakthrough designation. Read the full release here: https://lnkd.in/eEuMSHaF #HealthcareInnovation #RadioPharmaceuticals #NuclearMedicine #Theranostics #Innovation #CXCR4
-
-
“Targeted radiopharmaceuticals are emerging as a new favorite among big pharma buyers and investors” is the verdict from Melanie Senior in her recent article for #NatureBiotechnology (Springer Nature Group). In this comprehensive and well-researched feature, she gives a knowledgeable overview of the fashionable nuclear medicine field, referencing also Pentixapharm’s CXCR4-based radiopharmaceutical program for CNS lymphoma. You can read the complete article right now just by clicking below! 👇 #radiopharmaceuticals #nuclearmedicine #theranostics #innovation #CXCR4
Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms
Move over, antibody–drug conjugates. Targeted radiopharmaceuticals are the new favorite. Here's what radiopharma leaders are saying: “You get a level of information you can’t get with any other modality. You can’t quantify where your ADCs [antibody–drug conjugates] or your CAR-Ts (chimeric antigen receptor-T cells) are." Alpha radiation is so potent that only a handful of molecules need reach the cancer cell to eliminate it, opening up “a crazy number of potential molecular targets,” including low-expression targets. “You have a very precise warhead that finds the tumor wherever it is. That could get into the mainstream." Still, "everyone is still learning; we need more data" “This is still a young industry. There is a lot more to come." Read the full piece at https://lnkd.in/eFFR888i
Precision radiation opens a new window on cancer therapy - Nature Biotechnology
nature.com
-
📈 The thriving dynamics of the radiopharmaceuticals market offers attractive value for investors. 💸 Many of the companies and scientific approaches are “Made in Germany”. 🇩🇪 Julia Groß recently met with Eckert & Ziegler SE and Pentixapharm AG to discuss their unique insights, which we are excited to see are featured in this week’s issue of FOCUS MONEY. Recommended reading! #radiopharmaceuticals #nuclearmedicine #theranostics #innovation #CXCR4
Sieben Milliarden Dollar schwer soll der Markt für Radiopharmaka laut Evaluate schon 2030 sein. Je nachdem, was man heute schon dazu zählt, ist das mindestens eine Verdopplung innerhalb von sechs Jahren. Nach drei milliardenschweren Übernahmen herrscht Goldgräberstimmung bei Investoren, und das Geld sitzt seeehr locker - auch wenn Telix das Nasdaq-Listing nach Redaktionsschluss kurzfristig abgesagt hat. Spannende Geschichten, vor allem weil deutsche Wissenschaft und deutsche Unternehmen hier weit vorn dabei sind — nachzulesen ab heute im FOCUS MONEY e-Paper und ab Mittwoch auch gedruckt am Kiosk. PS Inklusive Interview mit Dr. Harald Hasselmann und Andreas Eckert von Eckert & Ziegler SE vor der geplanten Abspaltung von Pentixapharm.
-